SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Delisted > GTC Biotherapeutics (fka GTCB)

Re: Expiration dates of Rituxan patents

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 571
Posts 88,610
Boards Moderated 25
Alias Born 09/05/02
160x600 placeholder
Fed's Dudley: U.S. 'A Long Way' From Having Bubble Fighting Tool Kit
BOSTONFederal Reserve Bank of New York President William Dudley said Saturday the U.S. tool kit to deal with financial imbalances remains...
GE Strikes Two Deals to Sell Railcar Operations
Business News: Justices To Mull Future Of Class-Action Cases
FDA Approves Merck's Keytruda for Most Common Form of Lung Cancer -- Update
UAW, Ford Reach Tentative Deal Averting Plant Strike
Apple Acquires Artificial-Intelligence Startup VocalIQ
Saudi Arabia to Keep Investing in Energy Despite Lower Prices
Lawsuit Against Bank of America Moves Forward
Sirius, T-Mobile Spat Over Airwave Interference
Microsoft, Google Agree to Dismiss All Pending Patent Suits
DewDiligence Member Level  Saturday, 03/15/08 06:12:36 PM
Re: masterlongevity post# 8871
Post # of 19308 
Re: Expiration dates of Rituxan patents

According to DNA itself, the US patents that protect Rituxan are 5,677,180 (“Chimeric antibody with specificity to human B cell surface antigen”) and 5,736,137 (“Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma”).

The ‘180’ patent expires in Oct 2014 and the ‘1378’ patent expires in Apr 2015.

GTC believes that only the ‘180’ patent is relevant to GTC’s CD20 mAb program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist